Vaccine Partnering Terms and Agreements

Published: July 2014
No. of Pages: 1021
   

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in vaccine and adjuvant partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for vaccines

The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 880 links to online copies of actual vaccine deals along with contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since January 2009. The chapter is organized by specific vaccine and adjuvant technology type. Where contract available, the deal links via Weblink to an online version of the deal record providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in vaccine partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of vaccine technologies and products.

In addition, a comprehensive appendix is provided organized by vaccine partnering company A-Z, stage of development, theray area and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.

Vaccine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

Vaccine Partnering Terms and Agreements includes:

  • Trends in vaccine dealmaking in the biopharma industry since 2009
  • Analysis of vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life vaccine deals
  • Access to over 800 vaccine deal documents
  • The leading vaccine deals by value since 2009
  • Most active vaccine dealmakers since 2009
  • The leading vaccine partnering resources

In Vaccine Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy target
  • Specific technology type

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Vaccine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 880 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise vaccine rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Vaccine Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of vaccine and adjuvant deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of vaccine agreements with numerous real life case studies
  • Comprehensive access to over 880 actual vaccine deals entered into by the world’s biopharma companies
  • Detailed access to actual vaccine contracts enter into by the leading 50 big pharma and top 50 big biotech companies
  • Insight into the terms included in a vaccine agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Vaccine Partnering Terms and Agreements

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in vaccine dealmaking
2.1. Introduction
2.2. Vaccine partnering over the years
2.3. Big pharma vaccine dealmaking activity
2.4. Big biotech vaccine dealmaking activity
2.5. Most active in vaccine partnering
2.6. Vaccine partnering by deal type
2.7. Vaccine partnering by disease type
2.8. Average deal terms for vaccine partnering
2.8.1 Vaccine partnering headline values
2.8.2 Vaccine deal upfront payments
2.8.3 Vaccine deal milestone payments
2.8.4 Vaccine royalty rates
2.9. The anatomy of vaccine partnering
2.9. The anatomy of a vaccine deal
2.9. a. Case study 1: Stemline Therapeutics- University of Pittsburgh: March 2012
2.9.b. Case study 2: Agenus Bio- NewVac: December 2011

Chapter 3 – Leading vaccine deals
3.1. Introduction
3.2. Top vaccine deals by value
3.3. Top vaccine deals involving big pharma
3.4. Top vaccine deals involving big biotech

Chapter 4 – Big pharma vaccine deals
4.1. Introduction
4.2. How to use big pharma vaccine partnering deals
4.3. Big pharma vaccine partnering company profiles
Abbott
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Otsuka
Pfizer
Ranbaxy Laboratories
Roche
Sanofi
Shionogi
Takeda
Teva

Chapter 5 – Big biotech vaccine deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech vaccine partnering company profiles
Bavarian Nordic
Cangene
Dendreon
Elan
Emergent BioSolutions
Genmab
Morphosys
Spectrum Pharmaceuticals

Chapter 6 – Vaccine contracts dealmaking directory
6.1. Introduction
6.2. Company A-Z
Achaogen
Adamis Pharmaceuticals
Advaxis
Agenus Bio
Antigenics
Argos Therapeutics
Astellas Pharma
Avecia Biologics
AVI Pharma
Avimex
Bio-Matrix Scientific
BioCryst Pharmaceuticals
Biomedical Advanced Research and Development Authority
Bristol-Myers Squibb
Cadila Pharmaceuticals
Cedars-Sinai Medical Center
CPL Biologicals
Crucell
Dana-Farber Cancer Institute
Defense Threat Reduction Agency
Dendreon
Department of Health and Human Services
Department of Homeland Security
Diosynth
Dynavax Technologies
Elan
Emergent BioSolutions
Entest BioMedical
Fraunhofer USA
Galena Biopharma
Genocea Biosciences
GenVec
Gilead Sciences
GlaxoSmithKline
GlaxoSmithKline Biologicals
GlobeImmune
Gynecologic Oncology Group
Heat Biologics
Henry Schein
Hollister-Stier Labs
IBioPharma
ID Biomedical
ImmunoCellular Therapeutics
Inovio Pharmaceuticals
Isconova
ISSI-Strategy
Janssen Alzheimer Immunotherapy
Janssen Pharmaceutica NV
Johnson & Johnson
Kirin Pharma
Kyowa Hakko Kirin
LG Life Sciences
Maxygen
MD Anderson Cancer Center
Medarex
Merck and Co
Merix Bioscience
MorphoSys
Nabi Biopharmaceuticals
National Institutes of Health
NewVac
Novavax
Numoda
Ohio State University
Omnimmune
OncoSec Medical
Ortho-McNeil
Perseid Therapeutics
PharmAthene
RXi Pharmaceuticals
SIGA Technologies
Stemline Therapeutics
Symphony Dynamo
Talecris Biotherapeutics
The Regents of the University of California
Therinject
University of Connecticut
University of Miami
University of Pittsburgh
University of Washington
Vical
Xencor
6.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
6.4. By deal type
Asset purchase
Co-development
Collaborative R&D
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Research
Settlement
Supply
Technology transfer
Termination
Warranty
6.5. By therapy area
Gynaecology
Hospital care
Immunology
Infectives
Oncology
Psychiatry
Respiratory

Chapter 7 – Vaccine dealmaking directory by technology type
7.2. Deals by technology type
Vaccines
Adjuvant

Chapter 8 – Vaccine partnering resource center
8.1. Online vaccine partnering
8.2. Vaccine partnering events
8.3. Further reading on vaccine dealmaking

Table of Figures

Figure 1: Vaccine partnering since 2009
Figure 2: Big pharma – top 50 – vaccine deals 2009 to 2014
Figure 3: Big pharma vaccine deal frequency – 2009 to 2014
Figure 4: Big biotech – vaccine deals 2009 to 2014
Figure 5: Big biotech vaccine deal frequency – 2009 to 2014
Figure 6: Active vaccine dealmaking activity– 2009 to 2014
Figure 7: Vaccine partnering by deal type since 2009
Figure 8: Vaccine partnering by disease type since 2009
Figure 9: Vaccine partnering by infectives target since 2009
Figure 10: Vaccine partnering by oncology target since 2009
Figure 11: Vaccine deals with a headline value – by stage of development
Figure 12: Vaccine deal headline value distribution, US$million – discovery stage
Figure 13: Vaccine deal headline value distribution, US$million – preclinical stage
Figure 14: Vaccine deal headline value distribution, US$million – phase I stage
Figure 15: Vaccine deal headline value distribution, US$million – phase II stage
Figure 16: Vaccine deal headline value distribution, US$million – phase III stage
Figure 17: Vaccine deal headline value distribution, US$million – marketed stage
Figure 18: Vaccine deal headline value – median value by stage of development
Figure 19: Vaccine deals with upfront payment values – by stage of development
Figure 20: Vaccine deal upfront payment distribution, US$million – discovery stage deals
Figure 21: Vaccine deal upfront payment distribution, US$million – prelinical stage deals
Figure 22: Vaccine deal upfront payment distribution, US$million – phase I stage deals
Figure 23: Vaccine deal upfront payment distribution, US$million – phase II stage deals
Figure 24: Vaccine deal upfront payment distribution, US$million – phase III stage deals
Figure 25: Vaccine deal upfront payment distribution, US$million – marketed stage deals
Figure 26: Vaccine deal upfront value – median value by stage of development
Figure 27: Vaccine deals with milestone payment – by stage of development
Figure 28: Vaccine deal milestone payment distribution, US$million – discovery stage deals
Figure 29: Vaccine deal milestone payment distribution, US$million – prelinical stage deals
Figure 30: Vaccine deal milestone payment distribution, US$million – phase I stage deals
Figure 31: Vaccine deal milestone payment distribution, US$million – phase II stage deals
Figure 32: Vaccine deal milestone payment distribution, US$million – phase III stage deals
Figure 33: Vaccine deal milestone payment distribution, US$million – marketed stage deals
Figure 34: Vaccine deals with royalty rates
Figure 35: Components of the typical vaccine deal structure
Figure 36: Top vaccine deals by value since 2009
Figure 37: Top vaccine deals signed by big pharma value since 2009
Figure 38: Top vaccine deals signed by big biotech value since 2009
Figure 39: Online partnering resources
Figure 40: Forthcoming partnering events

Published By: Current Partnering
Product Code: Current Partnering25


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

  • Diagnostics Partnering Terms and Agreements

    The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detai...

  • Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

    The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s bioph...

  • Biomarker Partnering Terms and Agreements

    The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in bioma...

  • Companion Diagnostics Partnering Terms & Agreements

    The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access tthe companion diagnostics partnering deals and agreements entered intby the worlds leading healthcare companies....

  • Bioinformatics Partnering Terms and Agreements

    The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Discovery Stage Partnering Terms and Agreements

    The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare com...


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100